Alterity Therapeutics Limited American Depositary Shares
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ATHE Smart Score
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders. Show Less
Recent trades of ATHE by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ATHE's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to ATHE
Recent picks made for ATHE stock on CNBC
ETFs with the largest estimated holdings in ATHE
Flights by private jets registered to ATHE